期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 20, 期 1, 页码 69-82出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2018.1543403
关键词
Non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; pharmacologic therapy; clinical trial
资金
- Japan Society for the Promotion of Science KAKENHI [18K07637]
- Grants-in-Aid for Scientific Research [18K07637] Funding Source: KAKEN
Introduction: Multiple parallel factors are implicated in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). Currently recommended therapies for NASH include vitamin E and pioglitazone, besides dietary and lifestyle changes. Areas covered: This review focuses on the clinical development of several emerging drugs for the treatment of NASH and the impact of these drugs on current treatment standards. Expert opinion: Four drug classes (FXR agonists, CCR2/CCR5 antagonists, ASK1 inhibitors, and PPAR alpha/delta agonists) have moved into phase 3 trials for their investigation as NASH treatments. Results from phase 2 trials of other therapeutic agents with other pharmacological actions are also expected. The importance of combinational therapies with synergistic benefits engaging different targets, is now understood. Furthermore, studies have determined that the Mediterranean diet is beneficial for patients with NAFLD, while the traditional Okinawan diet is also considered useful. In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据